GSK’s antibiotic succeeds in late-stage gonorrhea trial with eye to addressing resistance
GSK’s oral antibiotic gepotidacin has hit the primary endpoint in a Phase III trial for urogenital gonorrhea, a growing public health concern due to increased …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
